CA2255662C - 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones - Google Patents

3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones Download PDF

Info

Publication number
CA2255662C
CA2255662C CA002255662A CA2255662A CA2255662C CA 2255662 C CA2255662 C CA 2255662C CA 002255662 A CA002255662 A CA 002255662A CA 2255662 A CA2255662 A CA 2255662A CA 2255662 C CA2255662 C CA 2255662C
Authority
CA
Canada
Prior art keywords
formula
group
aryl
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002255662A
Other languages
French (fr)
Other versions
CA2255662A1 (en
Inventor
Guang-Zhong Wu
Xing Chen
Yee-Shing Wong
Doris P. Schumacher
Martin Steinman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CA2255662A1 publication Critical patent/CA2255662A1/en
Application granted granted Critical
Publication of CA2255662C publication Critical patent/CA2255662C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics

Abstract

The invention relates to a process for producing a compound of formula (I) wherein R1, R2 and R3 are as defined in the specification, which comprises reacting a lactone with an imine to obtain a chiral diol of formula (IV) oxidizing the diol, condensing the resultant aldehyde with an enolether, hydrogenating the product, and chirally catalytically reducing the resultant ketone.

Description

'i 0 3-HYDROXY GAMMA-LACTON,~',~ASED
NANT T hl F I
BACK~j"OUND OF T,~~~E 1~IVENTION
This invention provides an improved process for producing azetidinones usefiul as hypocholesterolemic agents, as disclosed in co-owned, copending PCT Publication WO 95/08532. More particularly,.this . invention provides the steps of producing an azetidinone represented by the formula I.
~UM~,AARY OF THE 1NVEI~,TION
This invention provides a process for producing a compound of the formula:
OH / %Rt ~~.
v _ z wherein:
R~ , R2 and R3 are independently selected from the group consisting of:
(a) H;
(b) halo;
(c) -ORS, wherein: R5 is selected from the group consisting of H, Cy to Cs alkyl, aryl, aralkyl, heteroaryl, C2 to Cg alkynyl, C3 to C7 cycioalkyl, Cg to C7 cycloalkenyl and -C(O)RE; R6 is selected from the group consisting of C~ to CE alkyl, aryl and -OR7; and R~ is C1 to CE alkyl or aryl; and (d) -C(O)R8, wherein: R8 is selected from the group consisting of C1 to CE alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -OR9 and -N(R10}2; Rs is selected from the group consisting of C1 to CE alkyl and aryl; and each Rip is independently selected from the group consisting of H, C~ to CE
alkyl and aryl.
In particular, this process is useful for preparing 1-{4-fiuoro-phenyl)-3(R)-[3(S)-hydroxy-3-(4-fluorophenyl}propyl]-4(S)-(4-fluorophenyl)-2-azetidinone.
In general, this process comprises reaction of a 7-lactone and an imine to form a f3-lactam, followed by a chiral reduction. In particular, this invention is directed to a process for preparing a compound of formula I
OH / %R~
R3 ~ / '~~ N.

wherein R1, R2 and R3 are as defined above, comprising (a) reacting lactone of formula II
-o HO
with an imine of formula III
H ~ R2 -N
R~ ~ I
III
in the presence of a base, and optionally in the presence of a cyclization promoter, to obtain a chiral diol of formula IV
R~
HO OH
V, N
O / ~ R2 IV ;
(b) oxidizing the chiral diol of formula IV to the corresponding aldehyde of formula V
o ~/ R, HMI,..
N
O
/ .ii R2 V;
(c) condensing the aldehyde of formula V with an enolether of the formula E
OSi(CH3)3 R3 ~ W
followed by dehydration to obtain a compound of formula VI
o ~ / R, R3 i \
N
O
/ ~ R2 VI ;
(d) hydrogenating a compound of formula VI to form a compound of formula VII
~ y R, R3 , \
N
O / ~ R2 (e) conducting a chiral catalytic reduction of the compound of formula Vll to ob~in a compound of formula I;
(f) optionally, when any of R~, R2 or R3 is a benzyloxy or alkoxy group, converting said benzyloxy or alkoxy group to a hydroxy group to obtain a compound of formula I.
Also claimed are the following processes for preparing intermediates:
The process of reacting a lactone of formula ll with an imine of formula III in the presence of a base and optionally in the presence of a cyclization promoter to obtain a chiral diol of formula IV.
The process of oxidizing a chiral diol of formula IV to obtain an aldehyde of formula V.
The process of condensing an aldehyde of formula V with an enolether of formula E, followed by dehydration to obtain a compound of formula VI.
The process of hydrogenating a compound of formula VI to obtain a ketone of formula VII.
The process of hydrogentating a compound of formula VI"
OBn / \
R ' 3 '~' N
VI" O ~I R2 to obtain a compound of formula X
off /\
N
X O ~~ R2 The process of chirally reducing the keto group in the compound of formula VI" to obtain a compound of formula XI
OBn OH / \
R ' ~ / ~~.
3 . ~ N
O / y. R2 XI

WO 97!45406 PCT/US97/09666 Also claimed are the intermediates of formulas IV and VI.
DETAILED DESCRIPTION
As used herein the term "lower alkyl" means straight or branched alkyl chains of 1 to 6 carbon atoms. Alternatively, the number of carbon atoms may be specified. Thus, "C1 to C6 alkyl" means straight or branched alkyl chains of 1 to 6 carbon atoms. "Lower alkoxy" refers to alkoxy groups having 1 to 6 carbon atoms. Alternatively, the number of carbon atoms may be specified. Thus, "C1 to C6 alkoxy" means straight or branched alkoxy chains of 1 to 6 carbon atoms.
"Alkenyl" means straight or branched carbon chains having one or more double bonds in the chain, conjugated or unconjugated, and alkadienyl refers to chains having two double bonds in the chain.
Alternatively, the number of carbon atoms may be specified. Thus, "C~
to C6 alkenyl" means straight or branched alkenyl chains of 1 to 6 carbon atoms. "Alkynyl" means straight or branched carbon chains having one or more triple bonds in the chain. Alternatively, the number of carbon atoms may be specified. Thus, "Ci to C6 alkynyl" means straight or branched alkynyl chains of 1 to 6 carbon atoms.
Where an alkyl, alkenyi or alkynyl chain joins two other variables and is therefore bivalent, the terms alkylene, alkenylene and alkynylene are used.
"Aryl" (including substituted aryl) means a carbocyclic group containing from 6 to 15 carbon atoms and having at least one aromatic ring (e.g. aryl is a phenyl ring), with all available substitutable carbon atoms of the carbocyclic group being intended as possible points of attachment, said carbocyclic group being optionally substituted by 1 to 3 substituents selected from the group consisting of halo, alkyl, hydroxy, phenoxy, CF3, amino, alkylamino, dialkylamino and -N02.
"Aralkyl" means an alkyl group as defined above, in which an aryl group as defined above is substituted for one of the alkyl H atoms, e.g., benzyl, 4-vitro-benzyl' 4-methoxy benzyl and 4-chlorobenzyl.
"Acid" means an organic acid such as p-toluene sulfonic acid, trifluoroacetic acid or trifluoromethane sulfonic acid. Alternatively "acid"
means an inorganic acid such as sulfuric acid, hydrochloric acid or phosphoric acid.
"Hydrogenation catalyst" means a transition metal or its salt such as Pd/C, Pt/C, Raney nickel, Rh/C, RuIC, PdO, Pt0 or (PPh3)3RhCl.
"Cycloatkenyl" mean a cycloalkane of 4 to 10 carbon atoms with one or more double bonds in the ring.
"Bn" means benzyl. "Bn0" means benzyloxy.
"Cycloalkyl" means a saturated carbon ring of 3 to 6 carbon atoms, while "cycloalkylene" refers to a corresponding bivalent ring, wherein the points of attachment to other groups include all positional isomers. Alternatively, the number of carbon atoms may be specified.
Thus, "C3 to Cg cycloalkyl" means a saturated carbon ring of 3 to 6 carbon atoms.
"Halogeno" or "hal" or "halogen" refers to fluorine, chlorine, bromine or iodine radicals.
"Heteroaryl" means a 5- or 6-membered aromatic ring comprising 1 or 2 hetero atoms selected from the groups consisting of nitrogen and oxygen, for example pyridyl, pyrimidyl, imidazolyl, pyrrolyl, furanyl and oxazolyl. All positional isomers for a given heteroaryl group as defined herein are contemplated, for example 2-pyridyl, 3-pyridyl and 4-pyridyl.
Heteroaryl also means benzofused heteroaryl radicals formed by the bonding of a benzene radical to adjacent carbon atoms on a heteroaryl ring as defined above; examples are-indolyf, quinolyl, quinazolinyl, quinoxalinyl, indazolyl, benzoxazolyl, benzothienyl and benzofuranyl.
"Ph" means phenyl.
"Suitable inert organic solvent" means any organic solvent or combination of solvents that is unreactive in the reaction being conducted and is a solvent for the reactants. Such solvents used in the various reactions of this invention are identified in the discussion of reaction schemes and in the examples. Typical suitable solvents are halogenated compounds such as chloroform or dichloromethane;
heterocyclic compounds such as tetrahydrofuran (THF); 1,3-dimethyl-3,4,5,6 tetrahydro-2(1 H)-pyrimidino~e (DMPIi), dimethylformamide (DMF); dimethylsulfoxide (DMSO), lower alkanols (C1-G6 branched or * trade-mark _7_ straight chain alkanols) such as methanol, acetonitrile and carbocyclic aromatics such as toluene.
"Lewis acid" means an acid such as BF3~etherate, TiCl4 or AIC13.
In one aspect, the process of this invention comprises reaction of a y lactam and an imine to form a f3-lactam, followed by a chiral reduction according to Reaction Scheme A just below.
Reaction Scheme A
H V H / ~R~ O /%R~
O ~ ~~~ -~ H ~.,.
HO O N N

O / r R2 II
IV V
R~
O //, O //R~
R3 ~ / _ N .~ R ' w v .

O R ~ N
O
vll ~ ~ /R2 vl OH / %R~
'~.
/ O N
/ ~Rp I
This process, designated Method A, for producing compounds of off .. iiR~
formula I, wherein the moieties Rs ; ~
and have traps relative stereochemistry, comprises the following steps:
(a) reacting lactone of formula II with an imine of formula III in the presence of a strong base and optionally in the presence of a cyclization promoter, to obtain a chiral diol of formula IV;

_g_ (b) oxidizing the resulting chiral diol of formula IV to the corresponding aldehyde of formula V, for example with an oxidizing agent such as NaI04 or H5106;
(c) condensing the aldehyde of formula V with an enolether of the formula E
OSi(CH3)s R3 y I
followed by dehydration, for example acid catalyzed dehydration, to obtain a compound of formula VI;
(d) hydrogenation of a compound of formula VI with a hydrogenation catalyst agent such as hydrogen over palladium or hydrogen and (PPh3)RhCI on carbon to form a compound of formula VII;
(e) conducting a chiral catalytic reduction of the compound of formula VII with a borane, such as BH3~(CH3)2S or borane-THF
P ~ Ph ~.a ~N'BO
complex, and a chiral catalyst such as CHs , R, H N, ' O
g HN.B' CH3 or CH3 to obtain a compound of formula I;
(f) optionally, when any of R1, R2 or R3 is a benzyloxy or alkoxy group, converting said benzyloxy or alkoxy group to a hydroxy group, for example conducting a debenzylation reaction with a hydrogenating agent such as Pd/C/NH3HC02H or converting an alkoxy group to a hydroxy group by treatment with a Lewis acid to obtain a compound of formula I.
Method A is described in more detail is as follows. In step (a) of Reaction Scheme A, the lactone II is treated in a strong base such as lithium diisopropyiamide {LDA) with an imine of formula III under a dry atmosphere at a temperature in the range of about -15° to about -35°C
in a able inert organic solvent, e.g., DMPU, to produce a f3-lactam of _g_ formula IV. The reaction can be quenched by an acid such as acetic acid, and a traps f3-lactam of formula IV can be recovered by extraction followed by crystallization. Because traps f3-lactam cyclizes faster than cis f3-lactam, formation of a traps isomer is favored. This cyclization can be greatly accelerated by addition of additives such as LiCI or Liar (in a solvent such as DMF) resulting in further selectivity of traps f3-lactam formation. A crystallization step at this stage further improves the ratio of traps to cis fi-lactam to 95:5. In this reaction, use of a weaker coordination metal favors the formation of a traps f3-lactam of formula IV.
Thus, in this reaction, the use of sodium lithium hexamethyldisilyl amide (LiHMDA) as a base favors the formation of a traps f3-factam of formula IV as opposed to the cis isomer, and is preferred as opposed to Et2Zn/LDA or LiN(Pr-i)2. Also in this reaction, a lower temperature favors the formation of a traps f3-lactam of formula IV, as opposed to the cis isomer; and thus -35°C, is preferred over -25°C or -15°C.
In step (b), a f3-lactam of formula IV is oxidized by treatment with an oxidizing agent such as Na104 in a mixture of solvents such as THF
and water at a temperature between about 10°C and 25°C, with about 10°C to about 15°C being preferred. The ratio of the oxidizing agent, Na104, to diol is as follows: if the diol is present at 1.0 equivalent, then the Na104 is present at 1.0-2.0 equivalents, with 1.5 equivalent being preferred. The organic solvent for the reaction is a polar aprotic solvent such as acetronitrile or THF. The reaction is quenched by adding the reaction mixture to ice water. The resulting aldehyde of formula V is extracted and concentrated for use in the next step of the process.
In step (c), an aldehyde of formula V is reacted with the enolether of the formula E in an aprotic anhydrous organic solvent such as toluene in the presence of a Lewis acid such as BF3~etherate at a temperature in the range of about -78°C to about -20°C, with about -40°C
to about -20°C being preferred. The resulting aldol reaction can be quenched, for example with a mixture of NaHC03, t-BuOMe and hydrogen peroxide. In this reaction, the ratio of the f3-lactam and the enolether can be as follows: if the t3-lactam is present at 1.0 equivalent, then the enolether can be present at 0.9 to 1.2 equivalent with 1.0 equivalent being most preferred. The ratio of the f3-lactam and BF3~etherate can be as follows: if the fi-lactam is present at 1.0 equivalents, then BF3~etherate can be present at 1.0 to 1.5 equivalent, with 1.0 to 1.2 equivalent being preferred.
The resulting solution containing aldol product is extracted and concentrated for the dehydration step which involves treatment with molecular sieves and an organic acid such as p-toluene sulfonic acid monohydrate. If the aldol product is present at 1.0 equivalent, then the p-toluene sulfonic acid monohydrate can be present at 0.4 to 0.8 equivalent, with 0.5 to 0.6 equivalent being preferred. The solvents which may be employed in this reaction include toluene, t-butyl methyl ether (t-BuOMe), or benzene. The molecular sieves which are used in this reaction are 3A or 4A and are present in the reaction at 100% to 200% weight/weight as compared to the aldol compound. The reaction temperature is about 35°C to about 100°C, with the range of about 45°C
to about 60°C being preferred. The resulting compound of formula Vf is filtered and concentrated for use in the next step of this process. It will _be appreciated that a compound of formula VI is formed with cis and traps stereochemistry. That is, O / /R~ O / /R~
,,. :, , ,,. _ G
R3 ~ i --~I~N ~-- and R3 ~ i _...~I N l~,r O ~ ~R2 O ~ ~R2 VI cis VI traps . cis and traps about the azetidinone ring as shown by the arrows in these diagrams. Obtaining the compound with the traps stereochemistry is necessary in order to get the desired final products of the invention.
In step (d), the compound of formula VI is hydrogenated by treatment with a hydrogenating agent such as (Ph3P)3RhCI/H2 under a hydrogen atmosphere in an organic solvent such as a mixture of ethyl acetate (EtOAc) and CH30H; CH2C12; toluene; or ben2ene. The ratio of hydrogenating agent to the compound of formula VI is as follows: if the compound of formula VI is present at 1 mol %, then the hydrogenating agent is present at 0.1 to 10 mol %, with 0.3 mol % being preferred. The hydrogen atmosphere is present at 5 to 100 psi, with 40 to 60 psi being preferred. The reaction is run for 10 to 30 hours, with 14 to 16 hours being preferred. After extraction and concentration, the resulting compound of formula V11 is used in the next step.
In step (e), the compound of formula VII is chirally reduced by reaction in an anhydrous organic solvent such as CH2C12, THF or toluene, in the presence of a borane, such as BH3~(CH3)2S or borane-THF complex, and a chiral reduction catalyst such as R, R, ~~ Ph F't,,~ ~' o ~ ~o ~N~g~ HN~ ~ HN.B.
~CH3 , B~CH3 Or ~CH3 at a temperature in the range of about -30° to about 0°C, with a range of about -20° to about -10°C being preferred. The reaction is run for about 1 to about 20 hours, with a range of about 3 to about 10 hours being preferred. The ratio of the compound of formula VII to the chiral reduction catalyst is as follows: if the compound of formula Vlf ,is present at 1.0 equivalent, then the catalyst is present in a range of about 5 mol % to 100 mol %, with 5 mol % to i 0 mol % being preferred. If the compound of formula VII is present at 1.0 equivalent, then the borane (e.g., BH3~Me2S) is present at 0.7 to 1.0 equivalent, with 0.7 to 0.8 equivalent being most preferred. Concentration, extraction, and crystallization leads to the reduced compound of formula I.
For compounds of formula I wherein any one of R1, R2 or Rg is benzyloxy or alkoxy, said compounds can be converted to other compounds of formula I wherein R~, R2 or R3 is hydroxy by methods well known in the art. This is important in the preferred process described below, wherein the desired compound of formula I has a hydroxy group at R~, but wherein the hydroxy group must be protected during the process, preferably by a benzyl group. The protected compound of formula I is debenzylated by treatment with a hydrogenating agent such as Pd/C/HC02NH4 under a hydrogen atmosphere: the concentration of Pd/C is 5% to 20% w/w, with 10-15% w/w being preferred. The ratio of compound of formula I to Pd/C used is 1.0 equivalent of compound of formula I to 2.0 to 5.0 equivalents of Pd/C, with 3.0 to 4.0 equivalent of Pd/C being preferred. Alternatively, hydrogen gas is used in the ranges from 5 psi (pound per square inch) to 100 psi with 20 to 40 psi being preferred. The solvents which can be employed at this stage of the reaction include CH30H, ethanol and i-propanol. Alkoxy groups can be converted to hydroxy groups by well-known methods, for example by treatment with a Lewis acid. Those skilled in the art will recognize that a reactive substituent at any of R~, R2 or R3, such as hydroxy or amino, can be protected with a suitable protecting group during the claimed process and said protecting group can be removed after the desired compound of formula 1 is obtained.
As noted above, when traps (3-lactam is formed in step (a), the corresponding cis product is also formed. The cis product is present at this stage of the process in an amount of 5% as compared to the traps product. The cis product may now be purged out by crystallization.
In a preferred embodiment of the invention, an imine of the formula F
H
/ -N
Bn0 ~ I llf is used and an enolether of the formula E' OSi(CH3)3 /~
F ~ E
is used. Consequently the compound of formula VI which results has the structural formula VI':
OBn O
_/ ~~.
F ~ / O N
/ \
V I' F
This resulting compound of formula VI' is hydrogenated as described above, the resulting in a compound of formula VII' OBn O / \
...
F I / _ O N
/ \
V I I' F
The compound of formula VII' is chirally reduced as described above, in the presence of a chiral reduction catalyst to obtain the reduced compound of formula f' OBn OH / \
F I ~ N
O / \
I~ F
The compound of formula I' is debenzylated by treatment with a hydrogenating agent such as Pd/C/HC02NH4 under a hydrogen atmosphere to obtain a compound of formula I"
OH
OH
...
F I ~ N
O / \
L, F
Alternatively, a compound of formula VI"
OBn R3 _., ~ / ~~.
N
VI" O ~''~ R2 may undergo a double hydrogenation step by reaction under hydrogen in the presence of a hydrogenation catalyst such as palladium on carbon to obtain a compound of formula X

off .,.
3 "'.
R ' N
O
X
The carbonyl adjacent to the R3-substituted phenyl group is then chirally reduced to obtain the corresponding compound of formula I"' off OH / ~
R3~i N
~!'' R2 In particular, a compound of formula VI' undergoes double hydrogenation as described to obtain a compound of formula X' OH

...
I
F i O N/~
x ~F .
Alternatively, in a process of the invention, a chiral reduction of the keto group in a compound of formula VI" may be conducted to obtain a compound of formula XI
OBn OH / ~
/ ...

N
Xl ~ / ~ R2 The double bond and the Bn0 group of this compound of formula XI
may then be hydrogenated to obtain the compound of formula I"'.
In particular, the compound of formula VI' can be chirally reduced to the compound of formula XI' 08n off r v / ...
Xr F
which can then be hydrogenated to obtain the compound of formula I"
In another process of the invention, a compound of formula VI"
may be converted by the Noyori reduction, i.e. using the catalyst (R)-Ru(BINAP)C12]2.NEtg. to obtain the compound of formula I"'. In particular, a compound of formula VI' can be reduced by this method to obtain a compound of formula I".
The starting material of formula li is known, and may be prepared from s-malic acid of the formula OH

O, r by reduction with BH3Me2~S followed by treatment with 5% NaBH4 to obtain a compound of the formula OH
HO

followed by cyclization of this compound with CF3C~2H to obtain the ~-Iactone of formula Il.
Alternatively, the 'y lactone of formula II may be obtained from glucose as described in U.S. Patent 5,292,939, HoHingsworth, An imine of formula IIt' may be prepared by reacting 4-benzyfoxy-benzaldehyde with 4-fluoroaniline in a polar organic solvent such as isopropanol at about room temperature. Other imines of the formula 111 may be prepared in a similar manner, by reacting the appropriate benzaldehyde derivatives and the appropriate aniline derivatives in isopropanol at room temperature for 2 to 3 hours and filtering the reaction mixture to give the product as a solid.
An enolether of the formula E' may be prepared by reacting 4-fluoro-acetophenone (which is a jcnown compound or may be prepared by known methods) in a solution of lithium diisopropylamide in a polar organic solvent such THF at a temperature in the range of about -30°C to about -35°C, with quenching by addition of Me3SiCl, concentration and distillation to obtain the enolether product. Other enolethers of formula E may be prepared in a similar manner.
The following examples illustrate the process of this invention:
Example 1 OBn 1. LDA/DMPU/DMF
O 2. H HO OH
~NC6H4F~p V~..
~O P-BnOC6H4 N
HO O

crystalline solid F
To a 5-liter 3 neck flask equipped with a mechanical stirrer, thermometer and addition funnel were added 500 mL of THF, 400 mL of DMPU and 120 mL (0.92 mol) of diisopropylamine. To the cooled mixture at -40 to -45°C was added dropwise 368 mL (0.92 mol) of 2.5 M
n-BuLi hexane solution. After 20 minutes, 47 g (0.46 mol) of lactone 3 diluted in 250 mL of THF was introduced and the reaction was agitated at -40 to -45°C for 2 hr. While agitating, 100 g (0.328 mo!) of imine was dissolved in 1 liter of DMF and then was added dropwise through the addition funnel into the reaction mixture at -40 to -45°C (30 min.).
The reaction was maintained at -25 to -30°C for 14 to 18 hrs and warmed to -13 to -17°C for another 4 hrs as followed by HPLC. i 4 g of LiCI was dissolved in 400 mL DMF in a 500 mL flask and added into the reaction mixture. After another 2 hrs at -15°C, 200 mL of HOAc was added to quench the reaction.
The reaction mixture was poured slowly into a 10-liter extractor containing 2 liters of 3 N HCI, 1 liter ice and 2.5 liters of EtOAc. The mixture was stirred for 15 min. and separated into layers. The aqueous layer was extracted with 1.0 liter and then with 0.5 liter of EtOAc. The combined organic layers were washed with 4 X 2 liter brine, concentrated, and 250 mL toluene was added to crystallize the traps lactam 4. The solid was filtered and dried at 50°C to give 85.5 g (64°!°
yield) lactam 4. Mp: 119-120°C. ~ H NMR (CDCl3) 7.38 (m, 5H), 7.22 (m, 4H), 6.90 (m, 4H), 5.04 (d, J=2.0, 1 H), 5.02 (s, 2H), 4.21 (m, 1 H), 3.70 (m,1 H), 3.6 (m,1 H), 3.52 (d, J=5.0,1 H), 3.15 (dd, J=5.2, 2.OHz), 2.85 (t, J=5.3, 1 H). ~3C NMR (CDCI3) 165.5, 160.7, 159.0, 157.5, 136.7, 133.6, 133.5, 129.3, 128.7, 128.2, 127.6, 127.4, 118.8, 118.6, 116.0, 115.5, 70.1, 69.5, 62.9, 56.8. HRMS: 408.1619 (MH+); Calc'd: 408.1611.
~~1~ -69.78 (c=0.121, THF). AnaLCalc'd for C24H23FNO4: C, 70.75; H, 5.44; N, 3.44. Found: C, 70.57; H, 5.56; N, 3.41.
Example 2 Bn Bn H
Na104 H
%

F F
To a 2 liter 3-neck flask equipped with a mechanical stirrer, thermometer and addition funnel were added sequentially 100 g (0.246 mmol) of lactam 4 and 800 mL of CH3CN. The mixture was cooled to 10°C with an ice bath. 63 g (0.295 mmol) of Na104 was dissolved in 800 mL of water in a 1 liter flask and transfered into the addition funnel. The Na104 solution was added into the reaction mixture at such a rate to maintain the temperature below 20°C (20 min:). After addition, the reaction was warmed to room temperature (r.t.) and stirred for 1 to 2 hrs as followed by NMR. The reaction was quenched into a 6 liter extractor containing 1.5 liters of ice-brine and 1.5 liters of toluene. The layers were stirred, separated anc! the aqueous layer was extracted with 500 mL of toluene. The combined organic layer was washed with 2 X 500 mL brine and concentrated to about 500 mL for the next reaction. MS:
376( MH+), 265, 239. ~H NMR (CDCI3) 9.82 (d, J=l.3Hz, 1 H), 7.31 (m, 5H), 7.17 (m, 4H), 6.88 (m, 4H), 5.32 (d; J=2.4HZ, 1 H), 4.98 (s, 2H), 4.15 (dd, J=2.4, 1.3Hz, 1 H).

Exam Ip a 3 OBn OSi(CH3js OBn O
F / /BF3~Et20 / ~..
H
2. PTSA/Sieves ~ , N
O / ~ F O

F F
5 To a 1 liter 3-neck flask equipped with a mechanical stirrer, thermometer and addition funnel were added at r.t. a solution of 100 g (0.267mmol) of aldehyde 5 (from Example 2) in 500 mL of toluene and 32 mL (0.267 mmol) of BF3~etherate. The mixture was cooled to -30°C
with a dry-ice bath. To the cooled mixture was added 56 g (0.267 mmol}
of enolether dropwise. The aldol reaction is completed in 5 min. To another 5 liter extractor were added 1 liter of saturated NaHC03 solution, 2 liters of t-BuOMe, and 150 mL of hydrogen peroxide (30%).
This quench solution was then cooled to 0°C with an ice bath. The aldol mixture was added dropwise into the quench solution at 0°C. The quenched mixture was allowed to warm to 15 to 20°C and the layers were separated. The aqueous layer was extracted with 1 liter toluene.
The combined organic layer was washed with 2 X 500 mL and concentrated to about 1 liter for dehydration.
To the 1 liter toluene solution of aldol product obtained above were added 200 g of molecular sieves and 25 g (0.133 mmol) of p-toluenesulfonic acid monohydrate. This mixture was heated to 40 to 50°C and monitored by NMR (2 to 4 hrs.). The reaction was cooled to 0°C and filtered through a pad of MgS04 and then 100 g silica gel. The filtrate was concentrated for the next step. Alternatively, the concentrated solution was added to 400 mL of heptane to precipitate the double bond product (99 g, 7.5% overall yields). MS: 496 (MH+), 359, 305, 238. ~ H NMR 8.01 (dd, J=8.5, 5.5Hz, 1 H), 7.40 (m, 7H), 7.30 (m, 6H), 7.18 (m, 2H), 7.22 (d, J=8.6, 1 H), 6.98 (t, J=8.5Hz, 1 H), 5.08 (s, 2H), 4.88 (d, J=2.4, 1 H}, 4.00 (m, 1 H).

_19_ Exam a 4 OBn OH
p ~ ~ O
Pd/C/HZ ~
F I / N F I / N
O / \ O
6A g F F
To a 1 liter Parr pressure bottle were added 0.8 g of Palladium on carbon (10%), 1.6 g (19.0 mmol) of NaHC03, 16 g (32.3 mmol) of compound 6A in 80 mL of EtOAc and 80 mL of CH3OH. The bottle was shaken under 30 psi of hydrogen pressure for 2 to 3 hrs as followed by TLC and HPLC. The reaction mixture was filtered through a pad of celite and washed with 200 mL toluene. The filtrate was washed in a 1 liter extractor with 200 mL brine and 2 mL of 3 N HCI. After separation of the layers, the organic layer was washed with 2 X 200 mL brine.
Concentration gave 11.8 g (90% yield) of compound 8.
(The reaction also could be carried out as follows: A mixture of 1 g of compound 6A in 10 mL of EtOAc, 1 mL of water, and 0.5 (w/w)% of Pd/C (wet) was shaken under 25 psi of H2 for ca. 4 hrs. The mixture was filtered through celite and washed with toluene. Concentration gave compound 8.
MS: 408 (MH+), 297. ~H NMR (CDC13) 7.95 (dd, J=8.6, 5.5Hz, 2H), 7.13-7.22 (m, 4H), 7.09 (t, J=8.6, 2H), 6.91 (t, J=8.6, 2H), 6.80 (d, J=8.6Hz, 2H), 4.65 (d, J=2.1, 1 H), 3.26 (m, i H), 2.33 (s, 1 H), 2.25 (m, 1 H). 13C (CDCIg) 197.7, 167.7, 164.5, 160.7, 157.5, 156.3, 133.8, 133.0, 130.9, 130.7, 129.2, 127.5, 118.6, 118.5, 116.2, 116.1, 116.0, 115.8, 115.7, 61.3, 59.7, 35.6, 23.3. Anal. Calc'd. for C24H19NF2O3~1/2 H20: C, 69.75; H, 4.47; N, 2.95; F, 9.11. Found: C, 69.23; H, 4.80; N, 3.36; F, 9.13.

WO 97!45406 PCT/US97/09666 Example 5 OH
O / ~ 2. B Ph ph I / ... N N.BO
F O / ~ gH3.Me S - / \

F F
The chiral catalyst was made following the standard procedure:
trimethylboroxine (28 mg, 0.22 mmol) was added into a solution of diphenylprolinol (75 mg, 0.3 mmol) in toluene (5ml) and the resultant solution was heated until refluxing. Toluene was distilled and another 5 ml of toluene was added and distilled out. The residue was used directly in the following reaction.
To a 50 mL oven-dried flask with a magnetic stirrer were added 2.4 g (5.9 mmol) of compound 8, 10 mL CH2C12, and 0.62 g (3'.0 mmol) of bistrimethylsilyl urea (BSU). After 0.5 hr, the reaction was filtered directly into another 50 mL oven-dried flask containing 0.05 eq. of the chiral catalyst at -20°C. To this was added 2.3 mL (4.7 mmol) of 2 N
BH3~Me2S. The reaction was stirred at -15 to -20°C and monitored by TLC and HPLC (3 to 5 hrs). 10 mL methanoI/HCl was added, followed by concentration. Water and t-BuOMe were added to the residue and it was extracted with t-BuOMe (x2) to give a crude product solution.
Concentration of t-BuOMe lead to the recovery of >50% catalyst as the HCI salt after filtration. Crystallization of crude product from fsopropanoI/H20 afforded 1.9 g of compound 8A. ~ H NMR(DMSO) 9.54 (s, 1 H), 7.32 (dd, J=8.3, 5.7Hz, 2H), 7.21 (m, 4H), 7.35 (m, 4H), 6.77 (d, J=8.3Hz, 2H), 5.3 (d, J=4.6Hz, 1 H), 4.82 (d, J=2.1 Hz, 1 H), 4.50 (m, i H), 3.10 (m, 1 H), 1,70-1.9 (m, 4H). ~3C NMR(DMSO) i 67.4, 162.3, 159.9, 159.3, 157.5, 156.9, 142.3, 142.3, 134.1, 134.0, 128.0, 127.7, 127.6, 118.4, 118.3, 116.0, 115.8, 114.9, 114.7, 71.2, 59.7, 59.5, 36.5; 24.6.

c OBn OBn O ~ ~ H2 (PhsP)s-----~..
i F ~ N
O N/ ~ F O

F F
The crude compound 6A, generated from dehydration step from 80 mmol of aldol condensation product, was dissolved in 120 ml of CH2C12 to which 2.2g (2.4 mmol) of the catalyst was added. The mixture was subjected hydrogenation at 60 psi for 18 hr. Concentration of the reaction gave a residue of the product, which was separated by column with hexane and EtOAc (90:10) to give 27.5 g pure product, 71 % from aldol condensation product as starting material. ~H NMR (CDC13) 7.98 (dd, J=8.5, 5.5Hz, i H), 7.41 (m, 5H), 7.25 (m, 4H), 7.12 (t, J=8.~, 2H), 6.55 (m, 4H), 5.04 (s, 2H), 4.68 (d, J=2.1, 1 H), 3.65 (m, 1 H), 3.28 (m, 1 H), 3.16 (m, 1 H), 2.40 (m, 1 H), 2.28 (m, 1 H).
Example 7 OBn Ph Ph OBn O / \ ~.w OH / \
~. ~ .N~ g'~ i,.
F i N CHs I i ~ N
O / ~ BHs'M~2S F O
/ \

F F
To a 250 mL oven-dried flask with a magnetic stirrer were added 6.2 g (12.5 mmol) of compound 6B and 60 mL of CH2C12. To the resulting solution at -20°C were added sequentially 0.1 equivalent of the chiral catalyst and 6.3 mL (12.5 mmol) of 2.0 N BH3~(CH3)2S over 2 h.
The reaction was allowed to warm to 0°C, it was stirred at that temperature for 1 h and quenched with CH30H. The quenched solution was concentrated and extracted with CH2C12. The organic layer was concentrated and the residue was recrystallized from EtOAc and hexanes to giue 4.1 g (70%) of 8B. The e.e. was determined by HPLC

and found to be 93%. 1 H NMR (CDC13): 8 7.45-7.15 (m, 11 H), 7.00-6.80 (m, 6H), 4.98 (s, 2H), 4.70-4.60 (m, 1 H), 4.50 (d, 1 H), 3.05-2.97 (m, 1 H), 2.20-2.10 (m, 1 H), 1.95-1.75 (m, 4H).
OBn O H
OH ~ ~ OH /
,,, Pd/C ~,, HC03-NH4+
F ~ N ~ F ~ N
O ~ ~ O /

To a flask were added Pd-C (10%) (1 g, 5% by w/w), ammonium bicarbonate (11.4 g, 181 mmole), compound 8B (18.1 g, 36.3 mmole) and CH30H (250 mL) carefully at r.t. under N2. HOAc was added to adjust the pH to 3-5 and the resultant mixture was heated at 45 to 55°C
until the reaction finished as determined by TLC (about 2-3hr): During . the reaction, the pH was controlled in the range of 3-5 by adding HOAc.
The reaction was filtered and the solvent evaporated. The residue was dissolved in t-BuOMe and washed with water. After drying over Na2S04 and evaporating the solvent, the product was purified by recrystallization in t-BuOMe/heptane and CH30H/waterto give 11.75 g (79%). ~H NMR
(DMSO): 9.54 (s, 1 H), 7.32 (dd, J=8.3, 5.7Hz, 2H), 7.21 (m, 4H), 7.35 (m, 4H), 6.77 (d, J=8.3Hz, 2H), 5.3 (d, ,!=4.6Hz, 1 H), 4.82 (d, J=2.1 Hz, 1 H), 4.50 (m, 1 H), 3.10 (m, 1 H), 1,70-1.9 (m, 4H). ~3C NMR (DMSO) 167.4, 162.3, 159.9, 159.3, 157.5, 156.9, 142.3, 142.3, 134.1, 134.0, 128.0, 127.7, 127.6, 118.4, 118.3, 116.0, 115.8, 114.9, 114.7, 71.2, 59.7, 59.5, 36.5, 24.6.
Example 9 OBn OH
O / ~ OH
H2yori catalyst v ~ ~.
/ N -i I / N
F O / ~ F O
6A I"
F F

(Cyclooctadienyl)ruthenium dichloride (10~ mg, 0.38 mmol) and (R)-2,2'-bis)diphenylphosphino)-1,1'-binaphthyl (BINAP) (250 mg, 0.40 mmol) were placed in a flask and connected to Schlenck apparatus with another flask at the opposite end. The entire apparatus was evacuated, then filled with N2. Toluene (10 mL) and Et3N (1 mL), after deoxygenation several times, was charged into the lower flask, which was then heated to 140-145°C for 4 h. After cooling to r.t., red solid precipitated out of solution. The solid was filtered and washed with degased toluene inside of the apparatus under N2. The entire apparatus was evacuated and the solid was dried.
Compound 6A (50 mg, O.t mmol), the catalyst, [(R)-Ru(BINAP)C12J2.NEt3, prepared above {<10 mg, <0.01 mmol) and CH30H (50 mL) with 1 drop of 2N HCI were charged in an autoclave under N2. The reaction was subjected to 850 psi HZ at 80°C for 48 h.
Major product (!") was found and matched in TLC and HPLC profile with the product of Example 5.
example 10 OBn Ph Ph OBn o / ~ ~''~ .,~C o H / ~
_/~,. ~N.B° /~,.
F ~ ~ N CIi3 ! i N
° ~ ~ BH3~Me~ F ° /

F F
To a mixture of 300 mg (0.61 mmol) of 6A and 0.1 equivalent of the chiral catalyst in 5 mL of CH2C12 at -15°C, 0.21 mL (0.4 rnmol) of 2.0 N BH3~(CH3)2S was added dropwise over 5 min. The reaction was allowed to warm to 0°C, it was stirred for 45 min. and quenched with CH30H. Concentration, followed by chromatography gave compound XI. The e.e. was determined to be 75%. ~ H NMR (CDC13): S 7.55-fi.82 (m, 18H), 5.95 (d, 1 H), 5.15 (d, 1 H), 4.98 (s, 2H), 4.65 (d, 1 H), 3.65 {d, 1 H).

Claims (16)

CLAIMS:
1. A process for producing a compound of the formula wherein:

R1, R2 and R3 are independently selected from the group consisting of:
(a) H;
(b) halo;
(c) -OR5, wherein: R5 is selected from the group consisting of H, C1 to C6 alkyl, aryl, aralkyl, heteroaryl, C2 to C6 alkynyl; C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(O)R6; R6 is selected from the group consisting of C1 to C6 alkyl, aryl and -OR7-and R7 is C1 to C6alkyl or aryl; and (d) -C(O)R8, wherein: R8 is selected from the group consisting of C1 to C6 alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -OR9 and -N(R10)2; R9 is selected from the group consisting of C1 to C6 alkyl and aryl; and each R10 is independently selected from the group consisting of H, C1 to C6 alkyl and aryl;
comprising (a) reacting lactone of formula II

with an imine of formula III

under a dry atmosphere, in an inert organic solvent, at a temperature range of about -15°C to about -35°C, in the presence of a base to obtain a chiral diol of formula IV

(b) oxidizing the chiral diol of formula IV to the corresponding aldehyde of formula V
(c) condensing the aldehyde of formula V in an aprotic anhydrous solvent, in the presence of a Lewis acid and in a temperature range of -78° to about -20°C, with an enolether of the formula E
followed by dehydration to obtain a compound of formula VI
(d) hydrogenating a compound of formula VI to form a compound of formula VII
(e) conducting a chiral catalytic reduction of the compound of formula VII with a chiral catalyst in an anhydrous organic solvent, in the presence of a borane; at a temperature of about -30°C to about 0°C to obtain a compound of formula I;
and, when desired (f) in a resulting compound of formula I in which any of R1, R2 or R3 is a benzyloxy or alkoxy group, converting said benzyloxy or alkoxy group to a hydroxy group to obtain a different compound of formula I in which said R1, R2 or R3 is hydroxy.
2. A process according to claim 1 for producing the compound of the formula comprising (a) reacting lactone of formula II
with an imine of formula III' under a dry atmosphere, in an inert organic solvent, at a temperature range of about -15°C to about -35°C, in the presence of a base to obtain a chiral diol of formula IV' (b) oxidising the chiral diol of formula IV' to the corresponding aldehyde of formula V' (c) condensing the aldehyde of formula V' in an aprotic anhydrous solvent, in the presence of a Lewis acid and in a temperature range of -78° to about -20°C, with an enolether of the formula E' followed by dehydration to obtain a compound of formula VI' (d) hydrogenating a compound of formula VI' to form a compound of formula VII' (e) conducting a chiral catalytic reduction of the compound of formula VII' in the presence of a chiral catalyst of the formula in an anhydrous organic solvent, in the presence of a borane, at a temperature of about -30°C to about 0°C to obtain a compound of formula I' and (f) debenzylating the compound of formula I'.
3. A process for the preparation of a compound of the formula wherein R1 and R2 are independently selected from the group consisting of:
(a) H;
(b) halo;
(c) -OR5, wherein: R5 is selected from the group consisting of H, C1 to C6 alkyl, aryl, aralkyl, heteroaryl, C2 to C6 alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(O)R6; R6 is selected from the group consisting of C1 to C6 alkyl, aryl and -OR7; and R7 is C1 to C6 alkyl or aryl; and (d) -C(O)R8, wherein: R8 is selected from the group consisting of C1 to C6 alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -OR9 and -N(R10)2; R9 is selected from the group consisting of C1 to C6 alkyl and aryl; and each R10 is independently selected from the group consisting of H, C1 to C6 alkyl and aryl;
comprising reacting a lactone of the formula with an imine of the formula wherein R1 and R2 are as defined above, under a dry atmosphere, in an inert organic solvent, at a temperature range of about -15°C to about -35°C in the presence of a base.
4. A process of claim 3 for preparing a compound of the formula which comprises reacting a compound of the formula with a compound of the formula
5. A compound of the formula wherein R1 and R2 are independently selected from the group consisting of:
(a) H;
(b) halo;

(c) -OR5, wherein: R5 is selected from the group consisting of H, C1 to C6 alkyl, aryl, aralkyl, heteroaryl, C2 to C6 alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(O)R6; R6 is selected from the group consisting of C1 to C6 alkyl, aryl and -OR7; and R7 is C1 to C6 alkyl or aryl; and (d) -C(O)R8, wherein: R8 is selected from the group consisting of C1 to C6 alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -OR9 and -N(R10)2;
R9 is selected from the group consisting of C1 to C6 alkyl and aryl; and each R10 is independently selected from the group consisting of H, C1 to C6 alkyl and aryl.
6. A compound according to claim 5 of the formula
7. A process for preparing a compound of the formula V
wherein R1 and R2 are independently selected from the group consisting of:
(a) H;
(b) halo;
(c) -OR5, wherein: R5 is selected from the group consisting of H, C1 to C6 alkyl, aryl, aralkyl, heteroaryl, C2 to C6 alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(O)R6; R6 is selected from the group consisting of C1 to C6 alkyl, aryl and -OR7; and R7 is C1 to C6 alkyl or aryl; and (d) -C(O)R8, wherein: R8 is selected from the group consisting of C1 to C6 alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -OR9 and -N(R10)2; R9 is selected from the group consisting of C1 to C6 alkyl and aryl; and each R10 is independently selected from the group consisting of H, C1 to C6 alkyl and aryl;
comprising oxidizing a chiral diol of formula IV
wherein R1 and R2 are as defined above.
8. A compound of the formula
9. A process for preparing a compound of formula VI
wherein R1, R2 and N3 are independently selected from the group consisting of:
(a) H;
(b) halo;

(c) -OR5, wherein: R5 is selected from the group consisting of H, C1 to C6 alkyl, aryl, aralkyl, heteroaryl, C2 to C6 alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(O)R6; R6 is selected from the group consisting of C1 to C6 alkyl, aryl and -OR7; and R7 is C1 to C6 alkyl or aryl; and (d) -C(O)R8, wherein: R8 is selected from the group consisting of C1 to C6 alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -OR9 and -N(R10)2; R9 is selected from the group consisting of C1 to C6 alkyl and aryl; and each R10 is independently selected from the group consisting of H, C1 to C6 alkyl and aryl;
comprising condensing an aldehyde of formula V
wherein R1 and R2 are as defined above, with an enolether of the formula E
wherein R3 is as defined above, followed by dehydration.
10. A compound of the formula wherein R1, R2 and R3 are independently selected from the group consisting of:
(a) H;
(b) halo;

(o) -OR5, wherein: R5 is selected from the group consisting of H, C1 to C6 alkyl, aryl, aralkyl, heteroaryl, C2 to C6 alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(O)RE; R6 is selected from the group consisting of C1 to C6 alkyl, aryl and -OR7; and R7 is C1 to C6 alkyl or aryl; and (d) -C(O)R8, wherein: R8 is selected from the group consisting of C1 to C6 alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -OR9 and -N(R10)2;
R9 is selected from the group consisting of C1 to C6 alkyl and aryl; and each R10 is independently selected from the group consisting of H, C1 to C6 alkyl and aryl.
11. A compound according to claim 10 of the formula
12. A process for preparing a compound of the formula VII
wherein R1, R2 and R3 are independently selected from the group consisting of:
(a) H;
(b) halo;
(c) -OR5, wherein: R5 is selected from the group consisting of H, C1 to C6 alkyl, aryl, aralkyl, heteroaryl, C2 to C6 alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(O)R6; R6 is selected from the group consisting of C1 to C6 alkyl, aryl and -OR7; and R7 is C1 to C6 alkyl or aryl; and (d) -C(O)R8, wherein: R8 is selected from the group consisting of C1 to C6 alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -OR9 and -N(R10)2; R9 is selected from the group consisting of C1 to C6 alkyl and aryl; and each R10 is independently selected from the group consisting of H, C1 to C6 alkyl and aryl;
comprising hydrogenating a compound of formula VI
13. A process for preparing a compound of the formula X
wherein R2 and R3 are independently selected from the group consisting of:
(a) H;
(b) halo;
(c) -OR5, wherein: R5 is selected from the group consisting of H, C1 to C6 alkyl, aryl, aralkyl, heteroaryl, C2 to C6 alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(O)R6; R6 is selected from the group consisting of C1 to C6 alkyl, aryl and -OR7; and R7 is C1 to C6 alkyl or aryl; and (d) -C(O)R8, wherein: R8 is selected from the group consisting of C1 to C6 alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -OR9 and -N(R10)2; R9 is selected from the group consisting of C1 to C6 alkyl and aryl; and each R10 is independently selected from the group consisting of H, C1 to C8 alkyl and aryl;

comprising hydrogenating a compound of the formula VI"
14. A process for preparing a compound of the formula XI
wherein R2 and R3 are independently selected from the group consisting of:
(a) H;
(b) halo;
(c) -OR5, wherein: R5 is selected from the group consisting of H, C1 to C6 alkyl, aryl, aralkyl, heteroaryl, C2 to C6 alkynyl, C3 to C7 cycloalkyl, C3 to C7 cycloalkenyl and -C(O)R6; R6 is selected from the group consisting of C1 to C6 alkyl, aryl and -OR7; and R7 is C1 to C6 alkyl or aryl; and (d) -C(O)R8, wherein: R8 is selected from the group consisting of C1 to C6 alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, -OR9 and -N(R10)2; R9 is selected from the group consisting of C1 to C6 alkyl and aryl; and each R10 is independently selected from the group consisting of H, C1 to C6 alkyl and aryl;
comprising chirally reducing the compound of formula VI"
15. A process according to claim 1, wherein said chiral catalyst is selected from the group consisting of:
wherein Ph is phenyl.
16. A process according to claim 1 or 2, wherein said reacting in step (a) is carried out in the presence of a cylization promoter selected from LiCI and LiBr.
CA002255662A 1996-05-31 1997-05-28 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones Expired - Fee Related CA2255662C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/655,785 US5739321A (en) 1996-05-31 1996-05-31 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US08/655,785 1996-05-31
PCT/US1997/009666 WO1997045406A1 (en) 1996-05-31 1997-05-28 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones

Publications (2)

Publication Number Publication Date
CA2255662A1 CA2255662A1 (en) 1997-12-04
CA2255662C true CA2255662C (en) 2005-11-08

Family

ID=24630339

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002255662A Expired - Fee Related CA2255662C (en) 1996-05-31 1997-05-28 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones

Country Status (14)

Country Link
US (1) US5739321A (en)
EP (1) EP0906278B1 (en)
JP (1) JP3155759B2 (en)
AR (1) AR007314A1 (en)
AT (1) ATE226191T1 (en)
AU (1) AU3299497A (en)
CA (1) CA2255662C (en)
CO (1) CO4770966A1 (en)
DE (1) DE69716426T2 (en)
DK (1) DK0906278T3 (en)
ES (1) ES2185026T3 (en)
PT (1) PT906278E (en)
WO (1) WO1997045406A1 (en)
ZA (1) ZA974678B (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5886171A (en) * 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
ATE297892T1 (en) * 1998-12-07 2005-07-15 Schering Corp METHOD FOR PRODUCING AZETIDINONES
US6207822B1 (en) 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
EP1345895B1 (en) 2000-12-21 2006-12-27 Sanofi-Aventis Deutschland GmbH Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
ATE348649T1 (en) * 2001-01-26 2007-01-15 Schering Corp COMBINATIONS OF A STEROL ABSORPTION INHIBITOR AND A PPAR ACTIVATOR FOR THE TREATMENT OF CARDIOVASCULAR INDICATIONS
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
US6627757B2 (en) * 2001-03-28 2003-09-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
JP2005504091A (en) * 2001-09-21 2005-02-10 シェーリング コーポレイション Treatment of xanthomas with azetidinone as a sterol absorption inhibitor
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
US7671047B2 (en) 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176193B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176194B2 (en) 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
EP1601668B1 (en) 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
ES2318274T3 (en) * 2003-03-07 2009-05-01 Schering Corporation AZETIDINONA SUBSTITUTED COMPOUNDS, FORMULATIONS AND USE OF THE SAME FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA.
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
AR041089A1 (en) 2003-05-15 2005-05-04 Merck & Co Inc PROCEDURE AND PHARMACEUTICAL COMPOSITIONS TO TREAT ATEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED AFFECTIONS
AU2003259547A1 (en) * 2003-07-31 2005-02-14 Hetero Drugs Limited Ezetimibe polymorphs
WO2005049592A1 (en) 2003-11-24 2005-06-02 Hetero Drugs Limited A novel process for ezetimibe intermediate
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
CA2550215A1 (en) * 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
JP4590417B2 (en) * 2004-01-16 2010-12-01 メルク・シャープ・エンド・ドーム・コーポレイション NPC1L1 (NPC3) and method for identifying this ligand
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US20070244107A1 (en) * 2004-08-25 2007-10-18 Waters M Gerard Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
EP1817280A1 (en) * 2004-12-03 2007-08-15 Teva Pharmaceutical Industries Ltd. Ezetimibe polymorphs
US20060234996A1 (en) * 2005-04-14 2006-10-19 Itai Adin Novel crystalline form of ezetimibe and processes for the preparation thereof
ES2337727T3 (en) * 2005-06-20 2010-04-28 Schering Corporation USED PIPERIDINE DERIVATIVES AS H3 HISTAMINE ANTAGONISTS.
AR054482A1 (en) * 2005-06-22 2007-06-27 Astrazeneca Ab DERIVATIVES OF AZETIDINONE FOR THE TREATMENT OF HYPERLIPIDEMIAS
SA06270191B1 (en) * 2005-06-22 2010-03-29 استرازينيكا ايه بي Novel 2-Azetidinone Derivatives as Cholesterol Absorption Inhibitors for the Treatment of Hyperlipidaemic Conditions
US20070049748A1 (en) * 2005-08-26 2007-03-01 Uppala Venkata Bhaskara R Preparation of ezetimibe
EP1922304A2 (en) * 2005-09-08 2008-05-21 Teva Pharmaceutical Industries Ltd Processes for the preparation of (3r,4s)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe
KR20080059233A (en) 2005-10-21 2008-06-26 노파르티스 아게 Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
HUP0501164A2 (en) * 2005-12-20 2007-07-30 Richter Gedeon Nyrt New industrial process for the production of ezetimibe
WO2007119106A2 (en) * 2005-12-22 2007-10-25 Medichem, S.A. Processes for preparing intermediate compounds useful for the preparation of ezetimibe
WO2007100807A2 (en) 2006-02-24 2007-09-07 Schering Corporation Npc1l1 orthologues
WO2007108007A1 (en) * 2006-03-23 2007-09-27 Unichem Laboratories Limited A process for the preparation of ezetimibe via a novel intermediate
EP2007718A2 (en) * 2006-03-29 2008-12-31 Medichem, S.A. Processes for preparing ezetimibe and intermediate compounds useful for the preparation thereof
AR060623A1 (en) * 2006-04-27 2008-07-02 Astrazeneca Ab COMPOUNDS DERIVED FROM 2-AZETIDINONE AND A PREPARATION METHOD
JP2009503119A (en) * 2006-08-29 2009-01-29 テバ ファーマシューティカル インダストリーズ リミティド Purify (3R, 4S) -4- (4-hydroxy protected-phenyl) -1- (4-fluorophenyl) -3- [3- (4-fluorophenyl) -3-oxopropyl] azetidin-2-one how to
US20080103122A1 (en) * 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
WO2008032338A2 (en) * 2006-09-11 2008-03-20 Manne Satyanarayana Reddy Improved process for the preparation of ezetimibe and its intermediates
JP2010509216A (en) * 2006-11-02 2010-03-25 メルク エンド カムパニー インコーポレーテッド Heterocyclyl-substituted antihypercholesterolemic compounds
US20090047716A1 (en) * 2007-06-07 2009-02-19 Nurit Perlman Reduction processes for the preparation of ezetimibe
US20080319221A1 (en) 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
DE102007063671A1 (en) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh New crystalline diphenylazetidinone hydrates, medicaments containing these compounds and their use
CZ305066B6 (en) * 2008-02-25 2015-04-22 Zentiva, K.S. Process for preparing (3R, 4S)-l-(4-fiuorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3- hydroxypropyl)]-4-(4-hydroxyphenyl)-2-azetidinone
EP2128133A1 (en) * 2008-05-26 2009-12-02 Lek Pharmaceuticals D.D. Ezetimibe process and composition
PL387331A1 (en) 2009-02-24 2010-08-30 Instytut Chemii Organicznej Polskiej Akademii Nauk Method of manufacturing beta-lactam aldehyde compound, the intermediate compound, method of manufacturing the intermediate compound and application of the intermediate compound
US9388440B2 (en) 2009-04-01 2016-07-12 Mylan Laboratories Limited Enzymatic process for the preparation of (S)-5-(4-fluoro-phenyl)-5-hydroxy-1morpholin-4-yl-pentan-1-one, an intermediate of Ezetimibe and further conversion to Ezetimibe
WO2011140219A1 (en) 2010-05-04 2011-11-10 Codexis, Inc. Biocatalysts for ezetimibe synthesis
ES2372460B1 (en) 2010-07-09 2012-11-16 Moehs Ibérica S.L. NEW METHOD FOR THE PREPARATION OF EZETIMIBA.
CN102477008B (en) * 2010-11-22 2014-05-21 沈阳药科大学 Method for synthesizing ezetimibe
WO2012076030A1 (en) * 2010-12-10 2012-06-14 Pharmathen S.A. Process for the preparation of intermediate compounds useful in the preparation of ezetimibe
WO2012155932A1 (en) 2011-05-17 2012-11-22 Pharmathen S.A. Improved process for the preparation of ezetimibe
PL231215B1 (en) 2011-06-15 2019-02-28 Inst Chemii Organicznej Polskiej Akademii Nauk Process for the preparation of substituted azetidinones and intermediates for the synthesis thereof
CN103086938A (en) * 2011-10-28 2013-05-08 沈阳药科大学 Ezetimibe synthesis method
CN102531986A (en) * 2012-02-23 2012-07-04 苏州朗科生物技术有限公司 Preparation method for ezetimibe
CN103570574B (en) 2012-07-20 2016-04-13 中国科学院上海有机化学研究所 Intermediate used in a kind of synthetic method of ezetimibe and the method
CN103044305A (en) * 2013-01-24 2013-04-17 上海现代制药股份有限公司 Preparation method of ezetimibe intermediate
WO2015039675A1 (en) 2013-09-23 2015-03-26 Pharmathen S.A. Novel process for the preparation of ezetimibe intermediates
CN103739537B (en) * 2013-12-24 2015-05-20 连云港恒运医药科技有限公司 New synthesis method of ezetimibe
CN104072398B (en) * 2014-07-03 2016-02-03 河南省科学院化学研究所有限公司 A kind of method of synthesizing Ezetimibe
JP2016145173A (en) * 2015-02-09 2016-08-12 株式会社トクヤマ Method for producing (3r,4s)-1-(4-fluorophenyl)-[3(s)-hydroxy-3-(4-fluorophenyl)propyl]-(4-hydroxyphenyl)-2-azetidinone
CN107098841A (en) * 2016-02-19 2017-08-29 常州方楠医药技术有限公司 Intermediate used in the preparation method and this method of a kind of Ezetimibe
CN107033051A (en) * 2017-06-08 2017-08-11 武汉励合生物医药科技有限公司 A kind of preparation method of ezetimibe

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
AU7472896A (en) * 1995-11-02 1997-05-22 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon

Also Published As

Publication number Publication date
DE69716426D1 (en) 2002-11-21
DE69716426T2 (en) 2003-08-14
AU3299497A (en) 1998-01-05
ZA974678B (en) 1997-11-28
EP0906278A1 (en) 1999-04-07
ATE226191T1 (en) 2002-11-15
EP0906278B1 (en) 2002-10-16
CA2255662A1 (en) 1997-12-04
DK0906278T3 (en) 2003-02-17
PT906278E (en) 2003-01-31
JPH11511754A (en) 1999-10-12
WO1997045406A1 (en) 1997-12-04
AR007314A1 (en) 1999-10-27
ES2185026T3 (en) 2003-04-16
JP3155759B2 (en) 2001-04-16
CO4770966A1 (en) 1999-04-30
US5739321A (en) 1998-04-14

Similar Documents

Publication Publication Date Title
CA2255662C (en) 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US6096883A (en) 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5290941A (en) Facile condensation of methylbenzoxazoles with aromatic aldehydes
US5149838A (en) Intermediates for substituted azetidinones useful as anti-inflammatory and antidegenerative agents
US6590102B1 (en) Process for producing piperidinecarbinols
Datta et al. Stereoselective total synthesis of (−)-deoxoprosophylline
JP4585116B2 (en) Process for producing (-) cis-3-hydroxy-1-methyl-4- (2,4,6-trimethoxyphenyl) piperidine
KR20030029055A (en) A Process for the Preparation of 2,2-Dimethyl-5-(4-Chlorobenzyl)Cyclopentanone and an Intermediate Useful Therefor
EP0911335B1 (en) Method for producing furopyridine derivatives and intermediate compounds
CA2437954C (en) Process for producing quinolinecarboxyaldehyde derivative and intermediate
KR20030066594A (en) Intermediates for use in the preparation of vitamin e
US4234491A (en) Steroid synthesis process using mixed anhydride
US4477671A (en) 3-Acetoxy or benzyloxy-2-acetoxymethyl-6-[1-acetoxy-2-(N-tert-butylacetamido)ethyl]pyridine intermediates
JP2002533325A (en) Process for producing aryl piperidine carbinol intermediates and derivatives
JP4267125B2 (en) Method for producing pyridine alcohol derivative
Pearson et al. Organoiron complexes in organic synthesis: XXXII Synthesis of sterically crowded spirocyclic compounds using organoiron chemistry: An approach to acorane and cedrol synthesis
JPH0853414A (en) 4-amino-3-hydroxyphthalimidine and its production
IE52326B1 (en) Process and intermediates for preparing pirbuterol
MXPA00006631A (en) Method for producing (-)cis-3-hydroxy-1-methyl-4- (2,4,6-trimethoxyphenyl)-piperidine

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150528